QURE Pre-Submission Meeting with MHRA; UK MAA for AMT-130 Targets Q3 2026; FDA Type B Meeting Planned; 75% Disease Progression Slowing Demonstrated; Pursuing Global Registration Pathways
uniQure N.V. · PHARMACEUTICAL PREPARATIONS · Now $28.22
+39% in 7d after detection
Post-detection moves
1h
—
1d
-4.1%
3d
+6.1%
7d
+39%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS